DB:8XB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Biocartis Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8XB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

17.5%

8XB

-1.8%

DE Medical Equipment

2.6%

DE Market


1 Year Return

-50.1%

8XB

23.4%

DE Medical Equipment

8.1%

DE Market

Return vs Industry: 8XB underperformed the German Medical Equipment industry which returned 23.4% over the past year.

Return vs Market: 8XB underperformed the German Market which returned 8.1% over the past year.


Shareholder returns

8XBIndustryMarket
7 Day17.5%-1.8%2.6%
30 Day11.7%2.4%-0.08%
90 Day4.1%-0.07%12.1%
1 Year-50.1%-50.1%25.1%23.4%10.5%8.1%
3 Year-49.2%-49.2%147.7%141.9%6.4%-2.1%
5 Year-61.6%-61.6%249.6%235.4%15.2%-0.3%

Price Volatility Vs. Market

How volatile is Biocartis Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biocartis Group undervalued compared to its fair value and its price relative to the market?

3.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8XB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8XB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8XB is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.

PE vs Market: 8XB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8XB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8XB is good value based on its PB Ratio (3.3x) compared to the DE Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Biocartis Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

27.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8XB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8XB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8XB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8XB's revenue (26.7% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: 8XB's revenue (26.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8XB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biocartis Group performed over the past 5 years?

-11.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8XB is currently unprofitable.

Growing Profit Margin: 8XB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8XB is unprofitable, and losses have increased over the past 5 years at a rate of 11% per year.

Accelerating Growth: Unable to compare 8XB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8XB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.6%).


Return on Equity

High ROE: 8XB has a negative Return on Equity (-75.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is Biocartis Group's financial position?


Financial Position Analysis

Short Term Liabilities: 8XB's short term assets (€214.6M) exceed its short term liabilities (€23.2M).

Long Term Liabilities: 8XB's short term assets (€214.6M) exceed its long term liabilities (€160.7M).


Debt to Equity History and Analysis

Debt Level: 8XB's debt to equity ratio (161.4%) is considered high.

Reducing Debt: 8XB's debt to equity ratio has increased from 49.1% to 161.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8XB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 8XB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 6.4% each year


Next Steps

Dividend

What is Biocartis Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8XB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8XB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8XB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8XB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8XB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Herman Verrelst (46 yo)

3yrs

Tenure

€448,125

Compensation

Mr. Herman Verrelst has been Chief Executive Officer of Biocartis Group NV since August 31, 2017. Mr. Verrelst serves as the President of the Board at FOx Diagnostics. He serves as Director of European Ope ...


CEO Compensation Analysis

Compensation vs Market: Herman's total compensation ($USD528.20K) is below average for companies of similar size in the German market ($USD995.99K).

Compensation vs Earnings: Herman's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Herman Verrelst
CEO & Executive Director3yrs€448.13kno data
Piet Houwen
Chief Operating Officer1.33yrsno datano data
Benoit Devogelaere
Chief Technology Officer2.67yrsno datano data
Jean-Marc Roelandt
Chief Financial Officer0.33yrno datano data
Geert Maertens
Chairman of Scientific Advisory Board & Chief Scientific Officerno datano datano data
Renate Degrave
Head of IR & Corporate Communicationsno datano datano data
Susy Spruyt
Head of People & Organization5.58yrsno datano data
Erwin Sablon
Head of R&D and Alliance Management8yrsno datano data
Reginald Van Genechten
Head of Manufacturing & Supply Chain4.42yrsno datano data
Dirk Zimmermann
Global Head of Pharma Collaborations & Partnering1.25yrsno datano data
Erik Vossenaar
Vice President of Business Development4.58yrsno datano data

3.0yrs

Average Tenure

52yo

Average Age

Experienced Management: 8XB's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Herman Verrelst
CEO & Executive Director3yrs€448.13kno data
Geert Maertens
Chairman of Scientific Advisory Board & Chief Scientific Officerno datano datano data
Christian Reinaudo
Independent Chairman of the Board2.25yrs€73.50kno data
Jean-Louis Vincent
Member of Scientific Advisory Boardno datano datano data
Ann-Christine Sundell
Non Executive Independent Director2.58yrs€43.00kno data
Alberto Bardelli
Member of Scientific Advisory Boardno datano datano data
Eric Cutsem
Member of Scientific Advisory Boardno datano datano data
Roald Borré
Non-Executive Director6.58yrs€30.50kno data
Josep Tabernero
Member of Scientific Advisory Boardno datano datano data
Luc Gijsens
Non-Executive Independent Director2.58yrs€42.00kno data
Michael Press
Member of Scientific Advisory Boardno datano datano data
Pasi Jänne
Member of Scientific Advisory Boardno datano datano data

2.6yrs

Average Tenure

56yo

Average Age

Experienced Board: 8XB's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biocartis Group NV's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biocartis Group NV
  • Ticker: 8XB
  • Exchange: DB
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €280.783m
  • Shares outstanding: 56.38m
  • Website: https://www.biocartis.com

Number of Employees


Location

  • Biocartis Group NV
  • Generaal De Wittelaan 11 B
  • Mechelen
  • Antwerp
  • 2800
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCARTENXTBR (Euronext Brussels)YesNew Ordinary SharesBEEURApr 2015
8XBDB (Deutsche Boerse AG)YesNew Ordinary SharesDEEURApr 2015
0R72LSE (London Stock Exchange)YesNew Ordinary SharesGBEURApr 2015
BCARTBBATS-CHIXE (BATS 'Chi-X Europe')YesNew Ordinary SharesGBEURApr 2015

Biography

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncol ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/09 21:16
End of Day Share Price2020/08/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.